Clinical Trial: A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187973) titled 'A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)' on Sept. 08.

Brief Summary: This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

Study Start Date: Oct., 2025

Study Type: INTERVENTIONAL

Condition: Sickle Cell Disease

Intervention: DRUG: DISC-3405

DISC-3405 is administered subcutaneously.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Disc Medicine, Inc

Published by HT Digital Content Services with permission ...